(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > Clínica Universidad de Navarra > Oftalmología > DA - CUN - Oftalmología - Artículos de revista >

Oftalmopatía tiroidea: determinación de parámetros de actividad clínica de la oftalmopatía tiroidea como factor pronóstico de respuesta al tratamiento inmunosupresor
Otros títulos : Thyroid opfthalmopathy: clinical activity determination of thyroid ophthalmopathy as a prognostic factor of immunosupressive treatment response
Autor(es) : Belzunce, A. (Arnaldo)
Garcia-Gomez, P.J. (Pío J.)
Casellas, M. (M.)
Heras-Mulero, H. (Henar)
Moreno-Montañes, J. (Javier)
Palabras clave : Thyroid ophthalmopathy
Clinical activity score
Immunosuppressive treatment
Fecha incorporación: 2005
Editorial : Elsevier España
Versión del editor: http://dx.doi.org/10.4321/S0365-66912005001200005
ISSN: 0365-6691
Cita: Belzunce-Manterola A, Garcia-Gomez PJ, Casellas-Bravo M, Heras-Mulero H, Moreno-Montanes J. Oftalmopatía tiroidea: determinación de parámetros de actividad clínica de la oftalmopatía tiroidea como factor pronóstico de respuesta al tratamiento inmunosupresor. Arch Soc Esp Oftalmol 2005 Dec;80(12):705-712.
Resumen
Objective: To determine the usefulness of the clinical, biochemical and thyroid imaging parameters in patients with thyroid-associated ophthalmopathy, in predicting their response to immunosuppressive treatment. Methods: This retrospective study of 16 patients with thyroid ophthalmopathy considered a number of variables including sex, age, thyroid hormone levels, treatment of the thyroid dysfunction, clinical activity score (CAS), severity (NOSPECS) of the ophthalmopathy, signs in standardized A-mode ultrasonography, in CAT and/or NMR, and previously used treatments and their effectiveness. Results: The average age of the patients was 50.81 (S.D: 11.89) years; there were 5 males (31.3%) and 11 females (68.8%). The ophthalmopathy was classified as active in 10/16 patients (62.5%) and inactive in 6/16 (37.5%); and as moderate in 9/16 (56.25%) and severe in 7/16 (43.75%) according to the severity defined in NOSPECS. Ultrasonography was diagnostic in 100% of the cases. The severity decreased significantly (p ≤ 0.05), however the clinical activity decrease did not reach significance (p=0.38) during immunosuppressive therapy. Better results were obtained during treatment of patients with a higher CAS (p=0.04) and in those with more severe ophthalmopathy (p=0.02). There was a tendency for the patients with higher levels of TSI to respond better to the treatment (p=0.06). Conclusions: The CAS is the best parameter to quantify the activity of the disease and predicting the response to treatment. The higher the CAS and the more severe the ophthalmopathy, the better the response to treatment. No association existed between thyroid function and the activity or severity of the ophthalmopathy; or the effectiveness of treatment
Enlace permanente: http://hdl.handle.net/10171/23347
Aparece en las colecciones: DA - CUN - Oftalmología - Artículos de revista

Ficheros en este registro:
Fichero:  Arch Soc Esp Oftalmol 2005. 705.pdf
Descripción: 
Tamaño:  154,68 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.